Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

LXRX | NASDAQ
Chart Builder DCF Calculator
$1.75
-$0.04 (-2.23%)
At close: Nov 16, 2026, 4:00 PM ET
$1.77
+$0.02 (+1.14%)
After-hours: Nov 16, 2026, 7:54 PM ET
-2.23%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #287/1021 (Top 28%)

Key Statistics

Market Data

Market Cap $779.16M
1D Range
1.73 1.84
52W Range
1.14 2.64

Valuation (TTM)

PE -11.67
PB 4.76
EV/EBITDA -10.59

Valuation (NTM)

Forward PE N/A
Forward PEG 2.61
Price Target $6.00
Loading financial charts...

Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline...

Sector Healthcare
Industry Biotechnology
Employees 81
IPO Date Apr 7, 2000
Fiscal Year January - December

Latest News

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

3 months ago · globenewswire.com

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Lexicon Pharmaceuticals Q2 Earnings Call Highlights

3 months ago · marketbeat.com

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

3 months ago · zacks.com

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

3 months ago · globenewswire.com

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

4 months ago · globenewswire.com

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

6 months ago · globenewswire.com

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.03
Beat +46.92%
REV
$11.25M
Beat +171.43%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$6.00
Upside
+242.86%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.